Actively Recruiting
Epstein-Barr Virus Antibody and Epstein-Barr Virus DNA for Nasopharyngeal Carcinoma Screening
Led by Sun Yat-sen University · Updated on 2022-07-08
11625
Participants Needed
1
Research Sites
416 weeks
Total Duration
On this page
Sponsors
S
Sun Yat-sen University
Lead Sponsor
W
Wuzhou Red Cross Hospital
Collaborating Sponsor
AI-Summary
What this Trial Is About
The investigators intend to compare Epstein-Barr virus antibody and Epstein-Barr virus DNA screening efficacy in first-degree relatives of nasopharyngeal carcinoma patients.
CONDITIONS
Official Title
Epstein-Barr Virus Antibody and Epstein-Barr Virus DNA for Nasopharyngeal Carcinoma Screening
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Residents in Southern China
- Aged between 30 and 62 years
- Male gender
- First-degree relative of at least one nasopharyngeal carcinoma patient
- No medical history of nasopharyngeal carcinoma
- Eastern Cooperative Oncology Group score between 0 and 2
- Able to understand, sign, and date the informed consent form
You will not qualify if you...
- History of nasopharyngeal carcinoma
- Severe cardiovascular, liver, or kidney disease
- Currently on systemic steroid or immunosuppressant therapy
- Active autoimmune disease
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China, 510060
Actively Recruiting
Research Team
M
Ming-Yuan Chen, MD, PhD
CONTACT
S
Si-Yuan Chen, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here